Inhibition of Interleukin 10 Enhances Antitumor Immune Activity in Liver Metastases of Human Colorectal Cancer
-
August 1, 2026
Clinical Scorecard: Inhibition of Interleukin 10 Enhances Antitumor Immune Activity in Liver Metastases of Human Colorectal Cancer
At a Glance
| Category | Detail |
|---|---|
| Condition | Colorectal Cancer Liver Metastases |
| Key Mechanisms | Blockade of interleukin 10 enhances antitumor immune function. |
| Target Population | Patients with liver metastases from colorectal cancer. |
| Care Setting | Oncology research and clinical trials. |
Key Highlights
- IL-10 blockade potentiates CAR-T-mediated tumor cell death.
- Updated sample sizes confirmed findings remain statistically significant.
- Revised figures and results reflect corrected experimental data.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with colorectal cancer liver metastases undergoing CAR-T therapy.
IL-10 blockade may enhance the efficacy of CAR-T therapy.
Clinical Best Practices
- Ensure accurate reporting of experimental conditions and sample sizes.
- Regularly update figures and results to reflect correct data.
Related Resources & Content
Based on findings from:
Correction: Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases
Gut, 2026.
https://gut.bmj.com/content/75/8/e8
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
